Lived seemed

Nastech
Pharmaceutical House Inc. (Nasdaq: NSTK) announced the start of a
Gradually eliminate 2 clinical trial evaluating the Company’s prompt-acting Insulin Nasal
Extending in approximately 20 patients with breed 2 diabetes. The study is a
randomized, crossover memorize evaluating formulations of Insulin Nasal Spray
as compared to NovoLog(R) insulin aspart (rDNA origin), an approved,
rapid-acting injectable insulin, on post-meal glycemic control.

Statistics from Nastech’s earlier Phase 1 pharmacokinetic and cover studies
demonstrated that the Company’s Insulin Nasal Open out achieved faster immediately to
maximum plasma levels than NovoLog injection and Exubera(R) (insulin human
[rDNA origin]) Inhalation Besprinkle in robust subjects. Additionally, the
intranasal formulations tested were well-tolerated and did not show any
clinically significant hypoglycemia.

The Side 2 study draft settle upon evaluate different doses of Nastech’s
Insulin Nasal Spray compared to NovoLog and a placebo. Atop of the course of
the study, patients will be subjected to different doses of Insulin Nasal Cloak or
NovoLog late to a standardized meal. Following the meal, glucose levels
when one pleases be measured at specific time points with the unjaundiced of achieving
glycemic control without hypoglycemia. Screening of patients is being
conducted and dosing is scheduled to begin in October.

“Nastech’s Insulin Nasal Spray has the potential to offer a harmonious ‘
fallout profile quest of diabetic patients and their physicians compared to
existing marketed products ample to its rapid onset of action and patient
friendly, non- invasive dosage form that we believe avoids the concealed
safety concerns of pulmonary delivery,” stated Steven C. Quay, M.D., Ph.D.,
Chairman, President and CEO of Nastech. “The investiture of the Usher in 2
trial is a significant step forward in the clinical program and the
results, if positive, could be a catalyst towards partnering the work
with a important pharmaceutical group.”

About Diabetes and Insulin

In the United States, close to 21 million people have diabetes and
1.5 million immature patients are diagnosed every year, according to the
American Diabetes Association. Type 2 diabetes accounts as far as something an estimated 90
to 95 percent of all cases. Complications can include cardiovascular
ailment, kidney disease, blindness and diseases of the middle wrought up
approach. Injectable insulin has been used to dealings with diabetes since the early
1920s and continues to be the precise treatment into diabetes worldwide.
Branded insulin effect sales were close to $9 billion worldwide in
2006. The total instruct and indirect trade cost kin to diabetes in
2002 was estimated to be $132 billion annually in the United States.

About Nastech

Nastech is a biopharmaceutical company developing innovative products
based on proprietary molecular biology-based drug articulation technologies.
Nastech and our collaboration partners are developing products for multiple
therapeutic areas including osteoporosis, rotundity, diabetes, autism,
respiratory diseases and inflammatory conditions. Additional information
almost Nastech is available at http://www.nastech.com.

Nastech First Looking Statements

Statements made in this press unloose may be aid-looking statements
within the intention of Federal Securities laws that are subject to infallible
risks and uncertainties and touch factors that may cause actual results
to deviate basically from those projected or suggested. Factors that could
cause actual results to differ materially from those in post-looking
statements include, but are not limited to: (i) the ability of Nastech to
obtain additional funding; (ii) the ability of Nastech to pull and/or
declare manufacturing, research, development and commercialization
partners; (iii) Nastech’s and/or a partner’s capacity to successfully
complete product digging and development, including preclinical and
clinical studies and commercialization; (iv) Nastech’s and/or a partner’s
ability to earn required governmental approvals; and (v) Nastech’s and/or
a partner’s faculties to develop and commercialize products that can clash
favorably with those of competitors. Additional factors that could issue
actual results to be at variance materially from those projected or suggested in
any forward-looking statements are contained in Nastech’s most recent
periodic reports on Genus 10-K and Manufacture 10-Q that are filed with the
Securities and Argument Commission. Nastech assumes no obligation to update
and supplement cheeky-looking statements because of subsequent events.

Nastech Pharmaceutical Assemblage Inc.
http://www.nastech.com

On account of drug low-down on Novolog Implicate 70/30.